Redo craniotomy or bevacizumab for symptomatic steroid-refractory true or pseudoprogression following IMRT for glioblastoma.
Saved in:
| Title: | Redo craniotomy or bevacizumab for symptomatic steroid-refractory true or pseudoprogression following IMRT for glioblastoma. |
|---|---|
| Authors: | Cook TA; Central Coast Cancer Centre, Gosford Hospital, Gosford, New South Wales, Australia., Jayamanne DT; Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, New South Wales, Australia., Wheeler HR; Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, New South Wales, Australia.; Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia., Wong MHF; Central Coast Cancer Centre, Gosford Hospital, Gosford, New South Wales, Australia., Parkinson JF; Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.; The Brain Cancer Group, Sydney, New South Wales, Australia.; Department of Neurosurgery, Royal North Shore Hospital, Sydney, New South Wales, Australia., Cook RJ; Department of Neurosurgery, Royal North Shore Hospital, Sydney, New South Wales, Australia., Kastelan MA; Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, New South Wales, Australia.; The Brain Cancer Group, Sydney, New South Wales, Australia., Cove NJ; Central Coast Cancer Centre, Gosford Hospital, Gosford, New South Wales, Australia., Brown C; Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, New South Wales, Australia., Back MF; Central Coast Cancer Centre, Gosford Hospital, Gosford, New South Wales, Australia.; Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, New South Wales, Australia.; Genesis Cancer Care, Sydney, New South Wales, Australia.; Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.; The Brain Cancer Group, Sydney, New South Wales, Australia. |
| Source: | Neuro-oncology practice [Neurooncol Pract] 2021 Jun 09; Vol. 8 (5), pp. 601-608. Date of Electronic Publication: 2021 Jun 09 (Print Publication: 2021). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 101640528 Publication Model: eCollection Cited Medium: Print ISSN: 2054-2577 (Print) Linking ISSN: 20542577 NLM ISO Abbreviation: Neurooncol Pract Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2054-2577 |
|---|---|
| DOI: | 10.1093/nop/npab034 |
